|Articles|September 13, 2010

FDA on CV Risk in Diabetics

The FDA Guidance released in 2008 offers industry insight to why evaluation of heart risk in clinical trials is necessary.

ICE E-14 Step 2

Guidance for Industry

Integrated Cardiovascular Safety

Early Accuracy in New Drug Safety Analysis

Cardiac Safety: The Merits of ECG Centralization

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care

ByAndy Studna, Senior Editor

November 17th 2025

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data

ByAndy Studna, Senior Editor

November 14th 2025

Proactive Planning is Key to Mitigating Study Rescue

ByAshley Daigneau

November 14th 2025

ACT Brief: Site Satisfaction, eSource Data Transfers, and Gilead HIV Trial Results

ByAndy Studna, Senior Editor

November 14th 2025

© Ezume Images - © Ezume Images - stock.adobe.com

Gilead’s Single-Tablet Bictegravi/Lenacapavir Regimen Shows Positive Phase III ARTISTRY-1 Results in Virologically Suppressed Adults with HIV

ByAndy Studna, Senior Editor

November 13th 2025

FDA on CV Risk in Diabetics

Newsletter

Related Content

ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data

Proactive Planning is Key to Mitigating Study Rescue

ACT Brief: Site Satisfaction, eSource Data Transfers, and Gilead HIV Trial Results

Gilead’s Single-Tablet Bictegravi/Lenacapavir Regimen Shows Positive Phase III ARTISTRY-1 Results in Virologically Suppressed Adults with HIV

Trending on Applied Clinical Trials Online

ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care